IL138655A0 - Methods of cancer diagnosis using a chimeric toxin - Google Patents

Methods of cancer diagnosis using a chimeric toxin

Info

Publication number
IL138655A0
IL138655A0 IL13865599A IL13865599A IL138655A0 IL 138655 A0 IL138655 A0 IL 138655A0 IL 13865599 A IL13865599 A IL 13865599A IL 13865599 A IL13865599 A IL 13865599A IL 138655 A0 IL138655 A0 IL 138655A0
Authority
IL
Israel
Prior art keywords
chimeric toxin
methods
cancer diagnosis
gnrh
relates
Prior art date
Application number
IL13865599A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of IL138655A0 publication Critical patent/IL138655A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL13865599A 1998-03-24 1999-03-24 Methods of cancer diagnosis using a chimeric toxin IL138655A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/046,992 US6140066A (en) 1998-03-24 1998-03-24 Methods of cancer diagnosis using a chimeric toxin
PCT/IL1999/000166 WO1999049059A2 (fr) 1998-03-24 1999-03-24 Procedes servant a diagnostiquer le cancer au moyen d'une toxine chimere

Publications (1)

Publication Number Publication Date
IL138655A0 true IL138655A0 (en) 2001-10-31

Family

ID=21946472

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13865599A IL138655A0 (en) 1998-03-24 1999-03-24 Methods of cancer diagnosis using a chimeric toxin

Country Status (10)

Country Link
US (1) US6140066A (fr)
EP (1) EP1066390B1 (fr)
CN (1) CN1303438A (fr)
AT (1) ATE412756T1 (fr)
AU (1) AU758839B2 (fr)
CA (1) CA2323786A1 (fr)
DE (1) DE69939819D1 (fr)
IL (1) IL138655A0 (fr)
NZ (1) NZ507294A (fr)
WO (1) WO1999049059A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
US8962558B2 (en) 1997-07-04 2015-02-24 Johannes C. van Groeninghen Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
AU731703B2 (en) * 1997-07-11 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Pseudomonas exotoxin A-like chimeric immunogens
US7314632B1 (en) 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004535202A (ja) * 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
US20040013691A1 (en) * 2002-06-12 2004-01-22 Rosenblum Michael G. Immunotoxin as a therapeutic agent and uses thereof
CN1683416A (zh) * 2004-04-13 2005-10-19 李相哲 高效低毒的系列功能蛋白
CN100379869C (zh) * 2004-08-09 2008-04-09 生宝生物科技股份有限公司 超抗原融合蛋白及其应用方法
CN1768862A (zh) * 2004-10-26 2006-05-10 北京诺思兰德生物技术有限责任公司 一类能与表达GnRH受体的癌细胞特异结合且用锝－99m标记的蛋白
JP2008528633A (ja) * 2005-02-01 2008-07-31 リサーチ ディベロップメント ファウンデーション Ｂｌｙｓレセプターを標的化するためのｂｌｙｓ融合タンパク質およびｂ細胞増殖性疾患の処置方法
KR100808735B1 (ko) 2006-11-04 2008-02-28 진은철 황체호르몬 분비호르몬 및 독소분자의 복합체를유효성분으로 하는 건선 예방 및 치료제
CN101195822B (zh) * 2006-12-08 2012-08-08 湖南康都制药有限公司 高亲和性靶向融合蛋白
CN101343328B (zh) * 2008-08-25 2011-06-01 北京博翱泰生物技术有限公司 靶特异性双突变体融合蛋白质
CN103864938A (zh) * 2014-03-24 2014-06-18 北京博翱泰生物技术有限公司 靶特异性双突变体融合蛋白质及其制备工艺
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1239892A (en) * 1991-01-04 1992-08-17 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A method for constructing antigens
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma

Also Published As

Publication number Publication date
NZ507294A (en) 2003-05-30
ATE412756T1 (de) 2008-11-15
EP1066390B1 (fr) 2008-10-29
WO1999049059A2 (fr) 1999-09-30
US6140066A (en) 2000-10-31
CN1303438A (zh) 2001-07-11
DE69939819D1 (de) 2008-12-11
CA2323786A1 (fr) 1999-09-30
EP1066390A2 (fr) 2001-01-10
AU758839B2 (en) 2003-04-03
WO1999049059A3 (fr) 1999-12-02
AU2955199A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
IL138655A0 (en) Methods of cancer diagnosis using a chimeric toxin
WO2004032857A8 (fr) Therapie fondee sur les anticorps
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
AU2001258567A1 (en) Humanised antibodies to the epidermal growth factor receptor
AU2342897A (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
WO2003048328A3 (fr) Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
EP1476120A4 (fr) Methodes therapeutiques utilisant des anticorps anti-cd22
WO2002016413A8 (fr) Vaccins
IL147017A0 (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
PE20050712A1 (es) Anticuerpos rg1
PL367831A1 (en) Recombinant tumor specific antibody and use thereof
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2004058191A3 (fr) Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques
GR3026219T3 (en) Mouse monoclonal antibodies
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
AU2709295A (en) Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
WO2002058534A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du colon
CA3241997A1 (fr) Anticorps entierement humain ciblant gprc5d et recepteur antigenique chimerique (car) et son utilisation
WO1997029199A3 (fr) Peptides pour l'antigene prostatique specifique et leurs utilisations
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
WO2003072727A3 (fr) Anticorps monoclonaux specifiques d'egfrviii, ribozymes d'egfrviii et utilisations en detection, traitement ou prevention de cancer associe a l'egfrviii
NZ326436A (en) Ligand directed enzyme prodrug therapy for tumours using ligands that recognise and bind tumour receptors
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees